- Report
- April 2025
- 147 Pages
Global
From €3561EUR$3,999USD£3,105GBP
- Report
- March 2025
- 149 Pages
Global
From €3561EUR$3,999USD£3,105GBP
- Report
- January 2025
- 132 Pages
Global
From €3561EUR$3,999USD£3,105GBP
- Report
- February 2024
- 137 Pages
Global
From €4408EUR$4,950USD£3,844GBP
- Report
- July 2024
- 150 Pages
Global
From €5299EUR$5,950USD£4,620GBP
- Report
- June 2024
- 150 Pages
Global
From €5299EUR$5,950USD£4,620GBP
- Report
- October 2024
- 200 Pages
Global
From €3339EUR$3,750USD£2,912GBP
- Report
- May 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- March 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- March 2024
- 200 Pages
Global
From €3696EUR$4,150USD£3,223GBP
- Report
- August 2023
- 145 Pages
Global
From €2805EUR$3,150USD£2,446GBP
- Report
- March 2022
- 300 Pages
Global
From €4453EUR$5,000USD£3,883GBP
- Report
- February 2025
- 85 Pages
India
From €3117EUR$3,500USD£2,718GBP
- Report
- December 2024
- 85 Pages
India
From €3117EUR$3,500USD£2,718GBP
From €3117EUR$3,500USD£2,718GBP
- Report
- April 2025
- 200 Pages
Global
From €7080EUR$7,950USD£6,173GBP
- Report
- April 2025
- 200 Pages
Global
From €7080EUR$7,950USD£6,173GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1781EUR$2,000USD£1,553GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1781EUR$2,000USD£1,553GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1781EUR$2,000USD£1,553GBP

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump.
The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more